Former Chief Business Officer and Senior Vice President · CRESCENT BIOPHARMA, INC. (CBIO)

Armand Girard

FY2022 is the first fiscal year CompBrief holds for Armand Girard as a named executive officer of CRESCENT BIOPHARMA; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$754,253

Salary $412,833Stock awards $0Bonus $96,000

3rd of 3 named executive officers at Crescent Biopharma by FY2022 total.

3 named officers on file for CRESCENT BIOPHARMA, FY2022

Armand Girard’s pay file — $29

  • 1 fiscal year of pay, line by line
  • CBIO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRESCENT BIOPHARMA’s whole pay program stands against its peers

  • CRESCENT BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2023 (DEF 14A).

Free

Get Armand Girard’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Armand Girard compensation by year

CRESCENT BIOPHARMA Summary Compensation Table · the one fiscal year held
In US dollars, as CRESCENT BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$412,833
Bonus$96,000
Stock awards$0
Option awards$153,920
Non-equity incentive$0
Pension and deferred compensation$0
All other$91,500
Total$754,253

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 21, 2023, accession 0001558370-23-006383, and prior-year filings.

How this page was built: the CRESCENT BIOPHARMA, INC. filed document, accession 0001558370-23-006383. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU18,750$56,813—
Option1,354—$10.59
Option27,083—$4.72
Option26,041—$3.81
Option144,700—$1.11
Option47,700—$1.11

Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

CRESCENT BIOPHARMA’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Harout SemerjianPresident and Chief Executive Officer$1,434,922
Brian HahnChief Financial Officer and Senior Vice President$918,191
Armand Girard · this pageFormer Chief Business Officer and Senior Vice President$754,253

The full CRESCENT BIOPHARMA compensation record

free company brief

This page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Armand Girard's compensation dossier · One-time report. No refunds.